Diego C. D.

Focus areas include chronic liver pathology such as non‑alcoholic steatohepatitis, cholestatic disorders like primary biliary cholangitis, and complications of cirrhosis, together with post‑operative management of liver transplantation recipients.

• NASH with significant fibrosis
• Primary biliary cholangitis‑associated pruritus
• Compensated cirrhosis with portal hypertension
• Antibody‑mediated rejection after transplant
• Hepatic encephalopathy prevention

Clinical efforts aim to halt disease progression and support graft survival.

Therapeutic interests span atherosclerotic disease and metabolic risk, covering atherosclerotic cardiovascular disease, lipid disorders such as hypercholesterolemia and lipoprotein(a) disorder, and the interplay with diabetes‑related vascular complications.

• Primary prevention of ASCVD
• Familial hypercholesterolemia management
• Lipoprotein(a) lowering strategies
• Heart failure in metabolic syndrome
• Anticoagulation in atrial fibrillation

Interventions target risk reduction and long‑term cardiovascular health.

Investigations address blood cancers including acute myeloid leukemia, diffuse large B‑cell lymphoma, multiple myeloma and chronic lymphocytic leukemia, with emphasis on high‑risk and relapsed disease.

• Pediatric acute myeloid leukemia
• Relapsed/refractory diffuse large B‑cell lymphoma
• High‑risk multiple myeloma
• Chronic phase chronic myeloid leukemia
• B‑cell acute lymphoblastic leukemia

Clinical programs seek to improve survival through novel therapeutic combinations.

The investigator engages in the management of immune‑driven conditions such as ulcerative colitis, Crohn's disease, atopic dermatitis and systemic autoimmune processes including systemic lupus erythematosus.

• Moderate‑to‑severe ulcerative colitis
• Fistulizing perianal Crohn's disease
• Severe atopic dermatitis
• Antibody‑mediated rejection in transplantation
• Chronic graft‑versus‑host disease

Therapeutic strategies focus on targeted immunomodulation and disease control.